Diuretics in Chronic Kidney Disease

Introduction to Diuretic Therapy

The American College of Cardiology recommends thiazides as first-line agents alongside ACE inhibitors, ARBs, and calcium channel blockers for hypertension treatment across all CKD stages 1
Thiazide diuretics should be used as first-line agents for hypertension management across all CKD stages, including advanced disease with eGFR <30 mL/min/1.73 m², while loop diuretics are reserved primarily for managing fluid overload rather than blood pressure control 1, 2

Chlorthalidone 25 mg reduced 24-hour ambulatory blood pressure by 10.5 ± 3.1 mm Hg in patients with mean eGFR of 26.8 mL/min/1.73 m² 1, 2
Chlorthalidone is preferred over hydrochlorothiazide due to longer half-life and superior efficacy in major blood pressure trials 2
The National Kidney Foundation's KDOQI work group explicitly disagreed with older statements suggesting thiazides lose efficacy in advanced CKD 1, 2

Loop diuretics (furosemide, bumetanide, torsemide) should be reserved for patients with evidence of fluid retention—not used as first-line therapy for blood pressure control 3, 1
Clinical evidence of fluid retention: jugular venous pressure elevation, peripheral edema, pulmonary congestion 4, 3
The American College of Cardiology identifies furosemide as the most commonly used loop diuretic, though torsemide and bumetanide may offer superior absorption and longer duration of action 4, 3

Start chlorthalidone 12.5-25 mg daily as first-line therapy for patients with Stage 1-3 CKD (eGFR ≥30 mL/min/1.73 m²) 1
Consider chlorthalidone 25 mg daily for resistant hypertension in patients with Stage 4-5 CKD (eGFR <30 mL/min/1.73 m²) 1, 2
Furosemide: 20-40 mg once or twice daily initially, maximum 600 mg daily 3
Bumetanide: 0.5-1.0 mg once or twice daily, maximum 10 mg daily 3
Torsemide: 10-20 mg once daily, maximum 200 mg daily 3

Check electrolytes (sodium, potassium) and renal function within 2-4 weeks after initiating any diuretic therapy 1, 2
With thiazides: Check electrolytes and renal function 2-4 weeks after initiation, then every 6-8 weeks until blood pressure goal achieved 1, 2
Hypokalemia, hyponatremia, hyperuricemia, and volume depletion with thiazides 3, 2
Hyperkalemia when combining diuretics with ACE inhibitors or ARBs 2

When diuretics are used in patients with both CKD and heart failure, they must be combined with ACE inhibitors and beta-blockers—never used as monotherapy 4, 3
Diuretics produce symptomatic benefits more rapidly than any other drug for heart failure (within hours to days) 4
Diuretics should not be used alone in Stage C heart failure—even when successful in controlling symptoms, they cannot maintain clinical stability long-term without ACE inhibitors and beta-blockers 4

Do not automatically discontinue thiazides when eGFR falls below 30 mL/min/1.73 m² 1, 2
Do not use furosemide as first-line therapy for blood pressure control 1
Never combine ACE inhibitors with ARBs, regardless of diuretic use, as this increases risk without additional benefit 2
Avoid potassium-sparing diuretics when GFR <45 mL/min due to prohibitive hyperkalemia risk 1, 2